All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @alexa.maeck on TikTok · 321s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @alexa.maeck's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00The first time I got a ride, was the first ride in France.
  2. 0:02The new ride starts at noon.
  3. 0:03He wanted to take me to the second ride.
  4. 0:04He had a regular fight.
  5. 0:06But he was also a little older than me,
  6. 0:07but there were plenty of good moments.
  7. 0:10And he wanted to be voice-only,
  8. 0:12and very very very long people of this man's voice.
  9. 0:14And the second is the winner,
  10. 0:16he is also the winner.
  11. 0:17It's very complex.
  12. 0:19And he's a very good member.
  13. 0:21This is the one I learned.
  14. 0:22It's the winner of the day.
  15. 0:25And like I learned, he was also rich.
  16. 0:27I hope it gives you a little bit of comfort.
  17. 0:31Even if you are like the first one I can have.
  18. 0:35I think I'm going to do it for a bit.
  19. 0:38If I'm just going to do it, I'm going to do it again.
  20. 0:44The first thing I want is to sit down with my girlfriend.
  21. 0:49You'll see her here, right?
  22. 0:52We are just going to make a new type of a new type.
  23. 1:28This is what I used to say from your content,
  24. 1:32in my capacity to be done at least in aaca.
  25. 1:36=== Supermegan over your hentae?
  26. 1:38What is this?
  27. 1:40What's going on?
  28. 1:41I have to say that I'm not on the piano when I'm playing.
  29. 1:47I haven't been playing it...
  30. 1:49but first, I'm gonna turn this up a little bit.
  31. 1:51But now I need to turn the last round.
  32. 1:55he's just the best.
  33. 1:56He really is the best.
  34. 1:58And he's the best.
  35. 1:59And I think the best way to go is to get peers.
  36. 2:02And he's an NEAP.
  37. 2:05And while I spend so much time,
  38. 2:08he's a lot better.
  39. 2:10An interesting thing about this game is that
  40. 2:14it's super important for us to be able to learn
  41. 2:19about the threats that are really important.
  42. 2:53this is the first time I've ever seen,
  43. 2:56I've never seen this before.
  44. 2:59It's a very interesting story.
  45. 3:01I think it's the first time I've seen that.
  46. 3:03And that's the first time I've seen.
  47. 3:04I've seen my birthday.
  48. 3:06I've seen my birthday.
  49. 3:07My birthday is a bit drastic.
  50. 3:09I'm looking at a video on the comments
  51. 3:11and I'm looking at the comments
  52. 3:13I've got a video on the videos I've seen.
  53. 3:17I've finished this video.
  54. 3:19I've also gone to a Wednesday,
  55. 3:21but you have to be able to see the details of the video.
  56. 3:25I hope you have a great day.
  57. 3:27We will see you in the next video.
  58. 3:30It will be very nice to see you.
  59. 3:31I hope you enjoyed the video.
  60. 3:32If you are not sure you will be able to see it.
  61. 3:35It is so good to see you.
  62. 3:37I will be happy listening to you.
  63. 3:39Thank you for watching the video.
  64. 3:41And we will see you in the next video.
  65. 3:44I'll see you in the next video.
  66. 3:45Bye!
  67. 5:17This is coming.

Mounjaro 'Pasen tips': What TikTok fasting advice gets wrong

Alexa Maeck La Miss del Better

TikTok creator

27.7K viewsWatch on TikTok

Quick answer

The video is tagged with the Mounjaro hashtag and captioned with what appears to be a reference to tips, but the transcript contains no extractable clinical claims about tirzepatide dosing, efficacy, side effects, or administration. Tirzepatide (Mounjaro for diabetes, Zepbound for obesity) is a dual GIP/GLP-1 agonist with FDA approval supported by the SURMOUNT and SURPASS trial programs. Any guidance on its use must come from a licensed prescriber with access to a patient's full medical history.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded TirzepatideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Tirzepatide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 8 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For Mounjaro 'Pasen tips': What TikTok fasting advice gets wrong, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

Compounded Tirzepatide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Claim path

Keep researching this tirzepatide video claims cluster

Best for searchers deciding whether tirzepatide claims are stronger, safer, or more relevant than semaglutide claims.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "Mounjaro 'Pasen tips': What TikTok fasting advice gets wrong" from Alexa Maeck La Miss del Better. We read the clip as a GLP-1 social video fact-checks claim about Compounded Tirzepatide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The video is tagged with the Mounjaro hashtag and captioned with what appears to be a reference to tips, but the transcript contains no extractable clinical claims about tirzepatide dosing, efficacy, side effects, or administration.

The reason this review is not generic is the source wording and the canonical claim label "glp1 pasen tips mounjaro." In this clip, the useful excerpt is: "The first time I got a ride, was the first ride in France." That wording changes the review because it points to Compounded Tirzepatide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Tirzepatide Once Weekly for the Treatment of Obesity (2022), Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (2024), and Tirzepatide for Obesity Treatment and Diabetes Prevention (2025), plus the creator's own wording. Compounded Tirzepatide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Tirzepatide produced a mean 20.
People who land here are usually comparing the Compounded Tirzepatide claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Compounded Tirzepatide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

The video is tagged with the Mounjaro hashtag and captioned with what appears to be a reference to tips, but the transcript contains no extractable clinical claims about tirzepatide dosing, efficacy, side effects, or administration.

FormBlends verdict

Compounded Tirzepatide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Compounded Tirzepatide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The video is tagged with the Mounjaro hashtag and captioned with what appears to be a reference to tips, but the transcript contains no extractable clinical claims about tirzepatide dosing, efficacy, side effects, or administration. Tirzepatide (Mounjaro for diabetes, Zepbound for obesity) is a dual GIP/GLP-1 agonist with FDA approval supported by the SURMOUNT and SURPASS trial programs. Any guidance on its use must come from a licensed prescriber with access to a patient's full medical history.
  • The transcript is incoherent and yields zero verifiable health claims despite the Mounjaro hashtag reaching 27,700 viewers.
  • Tirzepatide produced a mean 20.9 percent body weight reduction at 15 mg in the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) under supervised clinical conditions.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Tirzepatide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Tirzepatide guide, cost path, safety notes, and provider review before acting.

Review Compounded Tirzepatide

What You'll Learn

  • The transcript is incoherent and yields zero verifiable health claims despite the Mounjaro hashtag reaching 27,700 viewers.
  • Tirzepatide produced a mean 20.9 percent body weight reduction at 15 mg in the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) under supervised clinical conditions.
  • FDA approved tirzepatide as Mounjaro for type 2 diabetes in 2022 and as Zepbound for chronic weight management in 2023. These are distinct indications.
  • Compounded tirzepatide is not FDA-approved and cannot be considered equivalent to brand-name Mounjaro or Zepbound in safety, sterility, or potency.
  • 6.3 percent of participants on the highest tirzepatide dose discontinued due to gastrointestinal side effects in SURMOUNT-1. Dose escalation decisions belong with a prescriber.
  • Auto-captioned health content on TikTok is frequently unintelligible to viewers relying on captions, representing an accessibility and accuracy failure simultaneously.
  • No social media video, regardless of view count, substitutes for a clinical evaluation before starting or adjusting a GLP-1 receptor agonist.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @alexa.maeck actually say?

Honestly? It's nearly impossible to tell. The transcript is incoherent from start to finish, a string of disconnected phrases about rides in France, piano playing, birthdays, and something called "Supermegan over your hentae." No medical claims surface in any legible form. The hashtag says Mounjaro, but the words don't.

This kind of transcript is typical of auto-generated captions on videos where the creator is speaking quietly, using a filter, or filming in a noisy environment. The caption reads "Pasen Tips" which may be a misspelling of "Pasen Tips" in Dutch, meaning Easter tips, or it may reference dosing advice in another language entirely. Without the actual audio, we cannot confirm what health information, if any, was communicated. Viewers saw 27,700 of whatever this was, which matters for public health even when content is garbled.

Does the science back this up?

There is no coherent claim here to evaluate against the literature. What we can do is provide the factual baseline for Mounjaro (tirzepatide) that viewers searching this hashtag deserve to have.

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist approved by the FDA in 2022 for type 2 diabetes and in 2023 as Zepbound for chronic weight management. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) found that participants taking 15 mg tirzepatide lost a mean of 20.9 percent of body weight over 72 weeks. That is a meaningful result, but it was achieved under controlled clinical conditions with lifestyle intervention, not from TikTok tips alone.

The SURPASS trial program also confirmed HbA1c reductions of up to 2.58 percentage points in type 2 diabetes patients (Frías et al., 2021, New England Journal of Medicine). These are drug-specific outcomes tied to prescribed doses under physician supervision.

What did they get wrong (or right)?

We cannot credit or fault the creator for any specific claim because the transcript does not yield one. That is itself the problem. If this video was meant to share Mounjaro tips, the information did not survive the transcription process in any usable form. Viewers relying on auto-captions, including those who are deaf or hard of hearing, received nothing actionable or verifiable.

What is worth flagging: the Mounjaro hashtag on TikTok has become a loose aggregator for weight loss content, some of it medically sound, some of it not. Videos in this category frequently circulate claims about self-titrating doses, mixing compounded tirzepatide with other peptides, or treating Mounjaro as equivalent to compounded versions. These are not safe messages. Compounded tirzepatide is not FDA-approved and cannot be claimed to be equivalent to Zepbound or Mounjaro in safety, potency, or sterility.

What should you actually know?

If you found this video through the Mounjaro hashtag hoping for guidance, here is what is actually grounded in evidence.

  • Tirzepatide is a prescription medication. No social media video replaces a clinical evaluation for whether it is appropriate for you.
  • The starting dose is determined by a licensed prescriber based on your health history. Do not adjust your dose based on what someone says worked for them on TikTok.
  • Common side effects include nausea, vomiting, diarrhea, and constipation, particularly during dose escalation. The SURMOUNT-1 trial reported that 6.3 percent of participants in the highest dose group discontinued due to gastrointestinal events (Jastreboff et al., 2022).
  • Pancreatitis, thyroid C-cell tumors in rodent models, and gallbladder disease are listed warnings. None of these are reasons to avoid the drug categorically, but they are reasons to have an ongoing conversation with a prescriber, not a comment section.
  • If you are considering tirzepatide for weight management, a regulated telehealth platform that conducts a proper intake and follows prescribing guidelines is a safer starting point than dosing tips from social media.

The bottom line

This video cannot be fact-checked in any conventional sense because it produced no legible claims. What it does illustrate is how quickly health-adjacent content spreads on TikTok regardless of whether the information is decipherable. Twenty-seven thousand views attached to a medical hashtag and zero extractable facts is not a neutral outcome. It means 27,700 people encountered content that signaled authority on a prescription medication and delivered nothing they could act on safely.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Alexa Maeck La Miss del Better · TikTok creator

27.7K views on this video

Pasen Tips 🥹 #mounjaro

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about the transcript?

The transcript is incoherent and yields zero verifiable health claims despite the Mounjaro hashtag reaching 27,700 viewers.

What does the video say about tirzepatide produced a mean 20.9 percent body weight reduction at?

Tirzepatide produced a mean 20.9 percent body weight reduction at 15 mg in the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) under supervised clinical conditions.

What does the video say about fda approved tirzepatide as mounjaro for type 2 diabetes in?

FDA approved tirzepatide as Mounjaro for type 2 diabetes in 2022 and as Zepbound for chronic weight management in 2023. These are distinct indications.

What does the video say about compounded tirzepatide?

Compounded tirzepatide is not FDA-approved and cannot be considered equivalent to brand-name Mounjaro or Zepbound in safety, sterility, or potency.

What does the video say about 6.3 percent of participants on the highest tirzepatide dose discontinued?

6.3 percent of participants on the highest tirzepatide dose discontinued due to gastrointestinal side effects in SURMOUNT-1. Dose escalation decisions belong with a prescriber.

What does the video say about auto-captioned health content on tiktok?

Auto-captioned health content on TikTok is frequently unintelligible to viewers relying on captions, representing an accessibility and accuracy failure simultaneously.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Alexa Maeck La Miss del Better, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.